Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | F2R | P25116 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461854 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BALDH1A1MAPK1KDM4E | |
| SCHEMBL314947 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BALDH1A1MAPK1KDM4E | |
| SCHEMBL15798061 | 0.89 | ITGB3 (0.36) | ITGB3ITGA2BALDH1A1MAPK1KDM4E | |
| SCHEMBL21995651 | 0.89 | ITGB3 (0.36) | ITGB3ITGA2BALDH1A1MAPK1KDM4E | |
| SCHEMBL20837312 | 0.84 | MAPK8 (0.44) | ITGB3ITGA2BALDH1A1MAPK1KDM4E | |
| SCHEMBL18185576 | 0.82 | ALDH1A1 (0.48) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL15085132 | 0.82 | BCHE (0.50) | ITGB3ITGA2BALDH1A1MAPK1KDM4E | |
| SCHEMBL4779124 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPK1KDM4EGAACYP2C9 | |
| SCHEMBL15797955 | 0.81 | CA12 (0.33) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL2224391 | 0.79 | ALDH1A1 (0.57) | ALDH1A1MAPK1KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111196808-B | Diazabicyclo compounds and their use | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11312719-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210107904-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2021-04-15 | — | — | US | disclosed |
| CN-111196808-A | Diazabicyclo compounds and their use | 南京圣和药业股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312719-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | ITGB3 2152/4885ITGA2B 1399/4885ALDH1A1 815/4885 |
| US-20210107904-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | ITGB3 2152/4885ITGA2B 1399/4885ALDH1A1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.